B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Infante, Maria Stefania; Salmanton-García, Jon; Fernández-Cruz, Ana; Marchesi, Francesco; Jakšić, Ozren; Weinbergerová, Barbora; Besson, Caroline; Duarte, Rafael F.; Itri, Federico; Valković, Toni; Szotkovski, Tomáš; Busca, Alessandro; Guidetti, Anna; Glenthøj, Andreas; Collins, Graham P.; Bonuomo, Valentina; Sili, Uluhan; Seval, Guldane Cengiz; Machado, Marina; Cordoba, Raul; Blennow, Ola; Abu-Zeinah, Ghaith; Lamure, Sylvain; Kulasekararaj, Austin; Falces-Romero, Iker; Cattaneo, Chiara; Van Doesum, Jaap; Piukovics, Klára; Omrani, Ali S.; Magliano, Gabriele; Ledoux, Marie-Pierre; de Ramon, Cristina; Cabirta, Alba; Verga, Luisa; López-García, Alberto; Da Silva, Maria Gomes; Stojanoski, Zlate; Meers, Stef; Lahmer, Tobias; Martín-Pérez, Sonia; Dávila-Vals, Julio; Van Praet, Jens; Samarkos, Michail; Bilgin, Yavuz M.; Karlsson, Linda Katharina; Batinić, Josip; Nordlander, Anna; Schönlein, Martin; Hoenigl, Martin; Ráčil, Zdeněk; Mladenović, Miloš; Hanakova, Michaela; Zambrotta, Giovanni Paolo Maria; De Jonge, Nick; Adžić-Vukičević, Tatjana; Nunes-Rodrigues, Raquel; Prezioso, Lucia; Navrátil, Milan; Marchetti, Monia; Cuccaro, Annarosa; Calbacho, Maria; Giordano, Antonio; Cornely, Oliver A.; Hernández-Rivas, José-Ángel; Pagano, Livio

doi:10.3389/fonc.2022.992137

prikaz prve stranice dokumenta B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Scientific paper - Original scientific paper

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Frontiers in Oncology, 12 (2022); 992137. https://doi.org/10.3389/fonc.2022.992137

Infante, Maria Stefania; Salmanton-García, Jon; Fernández-Cruz, Ana; Marchesi, Francesco; Jakšić, Ozren; Weinbergerová, Barbora; Besson, Caroline; Duarte, Rafael F.; Itri, Federico; Valković, Toni; Szotkovski, Tomáš; Busca, Alessandro; Guidetti, Anna; Glenthøj, Andreas; Collins, Graham P.; Bonuomo, Valentina; Sili, Uluhan; Seval, Guldane Cengiz; Machado, Marina; Cordoba, Raul; Blennow, Ola; Abu-Zeinah, Ghaith; Lamure, Sylvain; Kulasekararaj, Austin; Falces-Romero, Iker; Cattaneo, Chiara; Van Doesum, Jaap; Piukovics, Klára; Omrani, Ali S.; Magliano, Gabriele; Ledoux, Marie-Pierre; de Ramon, Cristina; Cabirta, Alba; Verga, Luisa; López-García, Alberto; Da Silva, Maria Gomes; Stojanoski, Zlate; Meers, Stef; Lahmer, Tobias; Martín-Pérez, Sonia; Dávila-Vals, Julio; Van Praet, Jens; Samarkos, Michail; Bilgin, Yavuz M.; Karlsson, Linda Katharina; Batinić, Josip; Nordlander, Anna; Schönlein, Martin; Hoenigl, Martin; Ráčil, Zdeněk; Mladenović, Miloš; Hanakova, Michaela; Zambrotta, Giovanni Paolo Maria; De Jonge, Nick; Adžić-Vukičević, Tatjana; Nunes-Rodrigues, Raquel; Prezioso, Lucia; Navrátil, Milan; Marchetti, Monia; Cuccaro, Annarosa; Calbacho, Maria; Giordano, Antonio; Cornely, Oliver A.; Hernández-Rivas, José-Ángel; Pagano, Livio More authors...

Cite this document

APA 6th Edition

Infante, M. S., Salmanton García, J., Fernández Cruz, A., Marchesi, F., Jakšić, O., Weinbergerová, B. ... Pagano, L. (2022). B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA). Frontiers in Oncology, 12.. doi: 10.3389/fonc.2022.992137

MLA 8th Edition

Infante, Maria Stefania, et al. "B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)." Frontiers in Oncology, vol. 12, 2022. https://doi.org/10.3389/fonc.2022.992137

Chicago 17th Edition

Infante, Maria Stefania, Jon Salmanton García, Ana Fernández Cruz, Francesco Marchesi, Ozren Jakšić, Barbora Weinbergerová, Caroline Besson, et al. "B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)." Frontiers in Oncology 12 (2022). https://doi.org/10.3389/fonc.2022.992137

Harvard

Infante, M. S., et al. (2022) 'B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)', Frontiers in Oncology, 12. doi: 10.3389/fonc.2022.992137

Vancouver

Infante MS, Salmanton García J, Fernández Cruz A, Marchesi F, Jakšić O, Weinbergerová B, and sur.. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA). Frontiers in Oncology [Internet]. 2022 October [cited 2024 December 25];12. doi: 10.3389/fonc.2022.992137

IEEE

M. S. Infante, et al., "B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)", Frontiers in Oncology, vol. 12, October 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:658338. [Accessed: 25 December 2024]

Cite this item: https://urn.nsk.hr/urn:nbn:hr:184:658338

Please login to the repository to save this object to your list.

Metadata

Title (english)	B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Author	Maria Stefania Infante
Author	Jon Salmanton-García
Author	Ana Fernández-Cruz
Author	Francesco Marchesi
Author	Ozren Jakšić
Author	Barbora Weinbergerová
Author	Caroline Besson
Author	Rafael F. Duarte
Author	Federico Itri
Author	Toni Valković
Author	Tomáš Szotkovski
Author	Alessandro Busca
Author	Anna Guidetti
Author	Andreas Glenthøj
Author	Graham P. Collins
Author	Valentina Bonuomo
Author	Uluhan Sili
Author	Guldane Cengiz Seval
Author	Marina Machado
Author	Raul Cordoba
Author	Ola Blennow
Author	Ghaith Abu-Zeinah
Author	Sylvain Lamure
Author	Austin Kulasekararaj
Author	Iker Falces-Romero
Author	Chiara Cattaneo
Author	Jaap Van Doesum
Author	Klára Piukovics
Author	Ali S. Omrani
Author	Gabriele Magliano
Author	Marie-Pierre Ledoux
Author	Cristina de Ramon
Author	Alba Cabirta
Author	Luisa Verga
Author	Alberto López-García
Author	Maria Gomes Da Silva
Author	Zlate Stojanoski
Author	Stef Meers
Author	Tobias Lahmer
Author	Sonia Martín-Pérez
Author	Julio Dávila-Vals
Author	Jens Van Praet
Author	Michail Samarkos
Author	Yavuz M. Bilgin
Author	Linda Katharina Karlsson
Author	Josip Batinić
Author	Anna Nordlander
Author	Martin Schönlein
Author	Martin Hoenigl
Author	Zdeněk Ráčil
Author	Miloš Mladenović
Author	Michaela Hanakova
Author	Giovanni Paolo Maria Zambrotta
Author	Nick De Jonge
Author	Tatjana Adžić-Vukičević
Author	Raquel Nunes-Rodrigues
Author	Lucia Prezioso
Author	Milan Navrátil
Author	Monia Marchetti
Author	Annarosa Cuccaro
Author	Maria Calbacho
Author	Antonio Giordano
Author	Oliver A. Cornely
Author	José-Ángel Hernández-Rivas
Author	Livio Pagano
Author's institution	University of Rijeka Faculty of Medicine (Department of Internal Medicine)
Scientific / art field, discipline and subdiscipline	BIOMEDICINE AND HEALTHCARE Clinical Medical Sciences Internal Medicine
Scientific / art field, discipline and subdiscipline	BIOMEDICINE AND HEALTHCARE Clinical Medical Sciences Infectology
Scientific / art field, discipline and subdiscipline	BIOMEDICINE AND HEALTHCARE Clinical Medical Sciences Oncology
Abstract (english)	Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
Keywords (english)
Language	english
Publication type	Scientific paper - Original scientific paper
Publication status	Published
Peer review	Peer review - international
Publication version	Published version
Journal title	Frontiers in Oncology
Numbering	vol. 12, 992137
e-ISSN	2234-943X
DOI	https://doi.org/10.3389/fonc.2022.992137
URN:NBN	urn:nbn:hr:184:658338
Publication	2022-10
Document URL	https://www.frontiersin.org/articles/10.3389/fonc.2022.992137/full
Type of resource	Text
Access conditions	Open access
Terms of use
Created on	2022-11-10 10:34:07